Feb 23, 2026: $GILD and $ACLX announced they signed a Merger Agreement and the FDA accepted the BLA for…
Filed with the SEC on · Summarized by InvestorsBot
Feb 23, 2026: $GILD and $ACLX announced they signed a Merger Agreement and the FDA accepted the BLA for anito‑cel (BCMA ddCAR) for relapsed/refractory multiple myeloma — a key step toward potential commercial launch. 🤝🔬 #Mergers #FDA
Gilead says the tender offer has not commenced; formal offer materials (Schedule TO) and Arcellx’s Schedule 14D‑9 will be filed with the SEC. Transaction remains subject to closing conditions, regulatory approvals and other risks. ⚠️ $GILD $ACLX #M&A #Investors
FDA BLA acceptance advances anito‑cel toward approval/commercialization; Gilead expects the deal could be accretive post‑approval but cautions CVR milestone payability, timing, integration and approval risks may affect outcomes. 💡 $GILD $ACLX #CAR_T #MultipleMyeloma